Nektar's new pathways to smarter medicine bring hope to millions of patients by creating innovative medicines that treat serious & widespread unmet medical needs.

Feb 24, 2025 · Nektar's lead product candidate, rezpegaldesleukin is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata.

Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of autoimmune disorders, chronic inflammatory conditions and cancer.

Medicines for which licenses have been granted to third-parties in the United States; also, information on U.S. medicines using Nektar technologies.

NKTR-255 is specifically engineered using Nektar’s expertise in polymer chemistry to mimic the natural biological activity of the body’s own IL-15, resulting in optimal activation of the IL-15 pathway.

Nektar is the global leader in polymer chemistry. Our approach to drug design focuses on creating new molecular entities with optimized drug pharmacology.

Dec 31, 2024 · SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023 .

Nektar Therapeutics is a global biopharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders.

SAN FRANCISCO, April 17, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced a strategic reprioritization and cost restructuring plan that includes a new pipeline focus on immunology, as well as several cost reduction initiatives, which the company expects will significantly reduce future operating expenses and extend its ...

March 27, 2017: Nektar Therapeutics Initiates Clinical Study of REZPEG (NKTR-358), a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders